This study investigates whether the gut hormone glucose-dependent insulinotropic polypeptide (GIP) can reduce feelings of nausea. GIP is naturally released after meals and is administered intravenously to healthy participants during the experiment. Nausea is induced using either glucagon-like peptide 1 (GLP-1), another gut hormone, or apomorphine, a medication known to trigger nausea. By combining these substances, the study aims to determine whether GIP can alleviate nausea. The findings may improve understanding of interactions between the gut and the brain.

Inclusion Criteria:

• Men or women, age of 18-60 years
• BMI between 19-27 kg/m2 (both included)
• informed consent

Exclusion Criteria:

• Current or past treatment with GLP-1 or GIP/GLP-1 receptor-targeting compounds within the last six months
• Gastrointestinal disorders that the investigator evaluates could interfere with induction of nausea (e.g. gastroparesis, functional dyspepsia and GI surgery)
• Neurological disorders affecting nausea (e.g. severe migraines and neuropathy)
• Any known eating disorders (e.g. anorexia nervosa and bulimia)
• Pregnancy or breastfeeding
• Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) (> 2 times normal values) or present hepatobiliary disease
• Kidney disease (estimated glomerular filtration rate (eGFR)<90 ml/min/1.73 m2) at screening
• Severe arteriosclerotic heart disease or heart failure (NYHA class II-IV)
• Glycated hemoglobin (HbA1c) ³ 48 mmol/mol and/or diagnosed type 1 or type 2 diabetes
• Any condition that the investigator evaluates would interfere with study participation